Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Androgen monotherapy raises dementia risk in prostate cancer patients

Publish date:: October 5, 2020

Key clinical point: Dementia risk appears to vary based on the type of androgen deprivation therapy used to treat prostate cancer.

Major finding: Prostate cancer patients treated with antiandrogen monotherapy showed a 34% increased risk of dementia compared to patients not treated with androgen deprivation therapy, but no similar increase in risk was noted for patients treated with gonadotropin-releasing hormone agonists or orchiectomy.

Study details: The data come from a cohort study of 23,651 male prostate cancer patients aged 66 to 79 years who were part of the Taiwan National Cancer Registry, the National Health Insurance Research Database, and the Taiwan National Death Registry.

Disclosures: The study was supported in part by Chang Gung Medical Foundation from the Maintenance Project of the Center for Big Data Analytics and Statistics of Chang Gung Memorial Hospital, and the Ministry of Science and Technology, Taiwan. The researchers had no financial conflicts to disclose.

Citation:

Huang W-K et al. JAMA Network Open. 2020 Aug 31. doi:10.1001/jamanetworkopen.2020.15189.

This Week's Must Reads

COVID-19 vaccine found effective but doctors watching for reactions, adverse events,

Study links sleep meds and dementia risk in older adults,

Childhood Hodgkin survivors have neurocognitive impairment,

Obesity, hypoxia predict severity in children with COVID-19,

Long-term safety and efficacy of teriflunomide for relapsing MS,

Must Reads in Dementia

Hemoglobin, age, RNA may predict mild dementia in kidney disease patients,

Reduced physical activity hinders dementia prevention efforts,

Baseline dementia predicts poor oral health,

Sauna time may mitigate dementia risk,

Rural residents with dementia have shorter survival than urban dwellers,